The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells

Cytokine

Volumn 71, Issue 2, 2015, Pages 154-160

  Ishtiaq, S ^a   Edwards, S ^b   Sankaralingam, A ^a   Evans, B A J ^c   Elford, C ^c   Frost, M L ^b   Fogelman, I ^b   Hampson, G ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Angiogenesis; Angiopoietin 1; Bisphosphonates; Osteoblasts; VEGF

Indexed keywords

ALENDRONIC ACID; ANGIOGENIC FACTOR; ANGIOPOIETIN 1; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; NITROGEN; VASCULOTROPIN; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; CULTURE MEDIUM; IMIDAZOLE DERIVATIVE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; VASCULOTROPIN A;

ADULT; ANIMAL CELL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSTEOBLAST; OSTEOCYTE; POSTMENOPAUSE; ANIMAL; BLOOD; BONE DENSITY; BONE DISEASES, METABOLIC; CELL LINE; CULTURE MEDIUM; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; MIDDLE AGED; MOUSE; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE;

MURINAE;

ALENDRONATE; ANGIOPOIETIN-1; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCITRIOL; CELL LINE; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DIPHOSPHONATES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; IMIDAZOLES; MICE; MIDDLE AGED; OSTEOBLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PROCOLLAGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84918540158     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.10.025     Document Type: Article

References (51)

1. Khosla S., Westendorf J.J., Modder U.I. Concise review: insights from normal bone remodeling and stem cell-based therapies for bone repair. Stem Cells 2010, 28(12):2124-2128.
2. Hauge E.M., Qvesel D., Eriksen E.F., Mosekilde L., Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 2001, 16(9):1575-1582.
3. Andersen T.L., Sondergaard T.E., Skorzynska K.E., Dagnaes-Hansen F., Plesner T.L., Hauge E.M., et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 2009, 174(1):239-247.
4. Portal-Nunez S., Lozano D., Esbrit P. Role of angiogenesis on bone formation. Histol Histopathol 2012, 27(5):559-566.
5. Street J., Lenehan B. Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism. J Orthop Surg Res 2009, 4:19.
6. Horner A., Bord S., Kelsall A.W., Coleman N., Compston J.E. Tie2 ligands angiopoietin-1 and angiopoietin-2 are coexpressed with vascular endothelial cell growth factor in growing human bone. Bone 2001, 28(1):65-71.
7. Saadeh P.B., Mehrara B.J., Steinbrech D.S., Dudziak M.E., Greenwald J.A., Luchs J.S., et al. Transforming growth factor-beta1 modulates the expression of vascular endothelial growth factor by osteoblasts. Am J Physiol 1999, 277(4 Pt 1):C628-37.
8. Steinbrech D.S., Mehrara B.J., Saadeh P.B., Greenwald J.A., Spector J.A., Gittes G.K., et al. VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism. Am J Physiol Cell Physiol 2000, 278(4):C853-60.
9. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997, 277(5322):48-50.
10. Zerlin M., Julius M.A., Kitajewski J. Wnt/Frizzled signaling in angiogenesis. Angiogenesis 2008, 11(1):63-69.
11. Henriksen K., Karsdal M., Delaisse J.M., Engsig M.T. RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 2003, 278(49):48745-48753.
12. Suzuki T., Miyamoto T., Fujita N., Ninomiya K., Iwasaki R., Toyama Y., et al. Osteoblast-specific Angiopoietin 1 overexpression increases bone mass. Biochem Biophys Res Commun 2007, 362(4):1019-1025.
13. Hampson G., Fogelman I. Clinical role of bisphosphonate therapy. Int J Womens Health 2012, 4:455-469.
14. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13(4):581-589.
15. Maruotti N., Corrado A., Neve A., Cantatore F.P. Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol 2012, 68(7):1013-1018.
16. Bellido T., Plotkin L.I. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone 2011, 49(1):50-55.
17. Idris A.I., Rojas J., Greig I.R., Van't Hof R.J., Ralston S.H. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008, 82(3):191-201.
18. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011, 22(12):2951-2961.
19. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(10):1479-1491.
20. Ruggiero S.L. Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci 2011, 1218:38-46.
21. Bottai V., Giannotti S., Dell'osso G., De Paola G., Menconi A., Falossi F., et al. Atypical femoral fractures: retrospective radiological study of 319 femoral fractures and presentation of clinical cases. Osteoporos Int 2013.
22. Santini D., Vincenzi B., Dicuonzo G., Avvisati G., Massacesi C., Battistoni F., et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003, 9(8):2893-2897.
23. Wehrhan F., Stockmann P., Nkenke E., Schlegel K.A., Guentsch A., Wehrhan T., et al. Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011, 112(2):216-221.
24. Tang X., Zhang Q., Shi S., Yen Y., Li X., Zhang Y., et al. Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer 2010, 126(1):90-103.
25. Marra M., Abbruzzese A., Addeo R., Del Prete S., Tassone P., Tonini G., et al. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets 2009, 9(7):791-800.
26. Caraglia M., Marra M., Naviglio S., Botti G., Addeo R., Abbruzzese A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother 2010, 11(1):141-154.
27. Street J.T., Wang J.H., Wu Q.D., Wakai A., McGuinness A., Redmond H.P. The angiogenic response to skeletal injury is preserved in the elderly. J Orthop Res 2001, 19(6):1057-1066.
28. Reffitt D.M., Ogston N., Jugdaohsingh R., Cheung H.F., Evans B.A., Thompson R.P., et al. Orthosilicic acid stimulates collagen type 1 synthesis and osteoblastic differentiation in human osteoblast-like cells in vitro. Bone 2003, 32(2):127-135.
29. Ogston N., Harrison A.J., Cheung H.F., Ashton B.A., Hampson G. Dexamethasone and retinoic acid differentially regulate growth and differentiation in an immortalised human clonal bone marrow stromal cell line with osteoblastic characteristics. Steroids 2002, 67(11):895-906.
30. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
31. Santini D., Vincenzi B., Avvisati G., Dicuonzo G., Battistoni F., Gavasci M., et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002, 8(5):1080-1084.
32. Di Salvatore M., Orlandi A., Bagala C., Quirino M., Cassano A., Astone A., et al. Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 2011, 44(2):139-146.
33. Soltau J., Zirrgiebel U., Esser N., Schachtele C., Totzke F., Unger C., et al. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res 2008, 28(2A):933-941.
34. Facchini G., Caraglia M., Morabito A., Marra M., Piccirillo M.C., Bochicchio A.M., et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther 2010, 10(6):543-548.
35. Acil Y., Moller B., Niehoff P., Rachko K., Gassling V., Wiltfang J., et al. The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. J Craniomaxillofac Surg 2012, 40(8):e229-35.
36. Sun J., Song F., Zhang W., Sexton B.E., Windsor L.J. Effects of alendronate on human osteoblast-like MG63 cells and matrix metalloproteinases. Arch Oral Biol 2012, 57(6):728-736.
37. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88(6):2095-2105.
38. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88(12 suppl):2961-2978.
39. Reid I.R. Osteonecrosis of the jaw: who gets it, and why?. Bone 2009, 44(1):4-10.
40. Lesclous P., Abi Najm S., Carrel J.P., Baroukh B., Lombardi T., Willi J.P., et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?. Bone 2009, 45(5):843-852.
41. Brown C., Gaspar J., Pettit A., Lee R., Gu X., Wang H., et al. ESE-1 is a novel transcriptional mediator of angiopoietin-1 expression in the setting of inflammation. J Biol Chem 2004, 279(13):12794-12803.
42. Wen D., Qing L., Harrison G., Golub E., Akintoye S.O. Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate. Oral Dis 2011, 17(4):427-432.
43. Wang J., Stern P.H. Dose-dependent differential effects of risedronate on gene expression in osteoblasts. Biochem Pharmacol 2011, 81(8):1036-1042.
44. Prasadam I., Zhou Y., Du Z., Chen J., Crawford R., Xiao Y. Osteocyte-induced angiogenesis via VEGF-MAPK-dependent pathways in endothelial cells. Mol Cell Biochem 2014, 386(1-2):15-25.
45. Fessel J. There are many potential medical therapies for a traumatic osteonecrosis. Rheumatology (Oxford) 2013, 52(2):235-241.
46. Catalano A., Morabito N., Basile G., Brancatelli S., Cucinotta D., Lasco A. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2013, 98(5):1911-1915.
47. Grundmann M., Haidar M., Placzko S., Niendorf R., Darashchonak N., Hubel C.A., et al. Vitamin D improves the angiogenic properties of endothelial progenitor cells. Am J Physiol Cell Physiol 2012, 303(9):C954-62.
48. Cardus A., Panizo S., Encinas M., Dolcet X., Gallego C., Aldea M., et al. 1,25-Dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009, 204(1):85-89.
49. Hokugo A., Christensen R., Chung E.M., Sung E.C., Felsenfeld A.L., Sayre J.W., et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 2010, 25(6):1337-1349.
50. Bedogni A., Saia G., Bettini G., Tronchet A., Totola A., Bedogni G., et al. Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws?. Oncologist 2012, 17(8):1114-1119.
51. Girgis C.M., Sher D., Seibel M.J. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010, 362(19):1848-1849.